Esperion Therapeutics Inc (ESPR)

05:08 AM

Esperion announces CCO Eric Warren to step down - Investing.com

05:08 AM

Apr 03, 2025

Esperion Therapeutics (ESPR) Down 15.8% Since Last Earnings Report: Can It Rebound? - Yahoo Finance

Apr 03, 2025

Apr 02, 2025

Diametric Capital LP Sells 312,829 Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) - MarketBeat

Apr 02, 2025

Apr 01, 2025

Esperion Appoints Robert E. Hoffman as New Director - TipRanks

Apr 01, 2025

Apr 01, 2025

Esperion appoints Robert Hoffman to board of directors By Investing.com - Investing.com UK

Apr 01, 2025

Apr 01, 2025

Esperion Appoints Robert E. Hoffman to Board of Directors - GlobeNewswire

Apr 01, 2025

Apr 01, 2025

Strategic Board Shake-up: Esperion Lands Former Kintara CEO Hoffman as Director - Stock Titan

Apr 01, 2025

Mar 31, 2025

Esperion stock hits 52-week low at $1.46 amid challenges By Investing.com - Investing.com South Africa

Mar 31, 2025

Mar 31, 2025

Esperion stock hits 52-week low at $1.46 amid challenges - Investing.com India

Mar 31, 2025

Mar 24, 2025

Esperion to Participate in 24th Annual Needham Virtual Healthcare Conference - GlobeNewswire

Mar 24, 2025

Mar 24, 2025

Exclusive: Esperion Reveals Next-Gen Drug Pipeline at Major Healthcare Conference - Stock Titan

Mar 24, 2025

Mar 21, 2025

BB Biotech AG Reduces Stake in Esperion Therapeutics Inc - GuruFocus

Mar 21, 2025

Mar 21, 2025

ESPR to Study Bempedoic Acid in Pediatric Familial Hypercholesterolemia - Nasdaq

Mar 21, 2025

Mar 20, 2025

Esperion Therapeutics Says FDA Clears Phase 3 Bempedoic Acid Trial in Hypercholesterolemia - MarketScreener

Mar 20, 2025

Mar 20, 2025

Esperion Aligns with U.S. Food and Drug Administration to Initiate Phase 3 Clinical Trials of Bempedoic Acid in Pediatric Heterozygous and Homozygous Familial Hypercholesterolemia - The Manila Times

Mar 20, 2025

Mar 20, 2025

Esperion Aligns with U.S. Food and Drug Administration to - GlobeNewswire

Mar 20, 2025

Mar 20, 2025

Esperion Therapeutics (ESPR) Aligns with U.S. Food and Drug Administration to Initiate Phase 3 Clinical Trials of Bempedoic Acid - StreetInsider.com

Mar 20, 2025

Mar 20, 2025

FDA Backs Esperion's Breakthrough Move into Pediatric Cholesterol Treatment - Stock Titan

Mar 20, 2025

Mar 19, 2025

Esperion Therapeutics chief commercial officer sells $3,617 in stock By Investing.com - Investing.com Australia

Mar 19, 2025

Mar 19, 2025

Esperion Therapeutics CFO sells $5,242 in stock By Investing.com - Investing.com Australia

Mar 19, 2025

Mar 19, 2025

Esperion Therapeutics CEO Koenig sells $19,622 in stock By Investing.com - Investing.com South Africa

Mar 19, 2025

Mar 19, 2025

Esperion Therapeutics CEO Koenig sells $19,622 in stock - Investing.com

Mar 19, 2025

Mar 19, 2025

Esperion Therapeutics CFO sells $5,242 in stock - Investing.com India

Mar 19, 2025

Mar 19, 2025

Esperion Therapeutics chief commercial officer sells $3,617 in stock - Investing.com

Mar 19, 2025

Mar 13, 2025

ESPR's Q4 Loss Narrower Than Expected, Revenues Increase Y/Y - MSN

Mar 13, 2025

Mar 11, 2025

Esperion stock hits 52-week low at $1.55 amid market challenges - Investing.com Australia

Mar 11, 2025

Mar 11, 2025

Esperion stock hits 52-week low at $1.55 amid market challenges By Investing.com - Investing.com South Africa

Mar 11, 2025

Mar 08, 2025

Q3 Earnings Forecast for ESPR Issued By HC Wainwright - Defense World

Mar 08, 2025

Mar 07, 2025

Esperion Therapeutics, Inc. SEC 10-K Report - TradingView

Mar 07, 2025

Mar 07, 2025

Esperion Therapeutics Inc. (ESPR) reports earnings - Quartz

Mar 07, 2025

Mar 07, 2025

Brokers Set Expectations for ESPR Q1 Earnings - Defense World

Mar 07, 2025

Mar 06, 2025

Esperion Therapeutics Retail Bulls Charge In As Stock Notches Best Day In 3 Months On Impressive Q4 - MSN

Mar 06, 2025

Mar 06, 2025

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives $6.75 Average Target Price from Analysts - Defense World

Mar 06, 2025

Mar 05, 2025

Esperion stock target holds at $4 on JMP’s optimistic outlook By Investing.com - Investing.com South Africa

Mar 05, 2025

Mar 05, 2025

Esperion stock target holds at $4 on JMP’s optimistic outlook - Investing.com

Mar 05, 2025

Mar 05, 2025

Esperion Therapeutics (NASDAQ:ESPR) Given “Buy” Rating at HC Wainwright - Defense World

Mar 05, 2025

Mar 05, 2025

Esperion Therapeutics: Q4 Earnings Snapshot - Barchart

Mar 05, 2025

Mar 05, 2025

Esperion stock hits 52-week low at $1.58 amid challenges By Investing.com - Investing.com Australia

Mar 05, 2025

Mar 04, 2025

Esperion Therapeutics Reports Strong Revenue Growth in 2024 - TipRanks

Mar 04, 2025

Mar 04, 2025

Esperion Therapeutics’ Earnings Call: Growth Amid Challenges - TipRanks

Mar 04, 2025

Mar 04, 2025

Esperion Therapeutics stock surges over 9% on strong Q4 results - Investing.com

Mar 04, 2025

Mar 04, 2025

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 04, 2025

Mar 04, 2025

Esperion Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 04, 2025

Mar 04, 2025

Esperion Therapeutics Q4 Loss Narrows - Nasdaq

Mar 04, 2025

Mar 04, 2025

Esperion Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2024 - Marketscreener.com

Mar 04, 2025

Mar 04, 2025

Esperion Therapeutics (ESPR) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance

Mar 04, 2025